Business Context and Reporting Period
This Form 8-K reports on events occurring on March 5, 2019, for Akers Biosciences, Inc. (the "Company"), a New Jersey corporation and emerging growth company. The filing details the results of a special meeting of shareholders held on this date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes
The primary material change is the shareholder approval to delist the Company's common stock from the Alternative Investment Market (AIM) operated by the London Stock Exchange.
- Voting Results: Proposal 1 to cancel admission to AIM was approved with 7,408,643 shares voted for, 171,463 against, and 70,304 abstaining.
- Quorum: 7,650,410 shares were present or represented, exceeding the required 33.34% quorum of the 12,482,708 shares entitled to vote.
- Effective Date: Trading on AIM is anticipated to cease at 7:00 a.m. (GMT) on March 29, 2019.
- Regulatory Impact: Upon delisting, finnCap Limited will cease to be the nominated adviser and broker in the UK. The Company will no longer be subject to AIM Rules but will remain subject to SEC and NASDAQ requirements.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future operations, or specific risk factors beyond the procedural changes associated with the delisting. The document confirms that all matters submitted to the vote were approved.
Investor Verification Checklist
- Verify the cessation of trading on AIM on March 29, 2019.
- Confirm the Company's continued compliance with NASDAQ listing standards following the UK delisting.
- Review subsequent filings for any impact on the Company's broker-dealer relationships in the UK.
- Check for any concurrent press releases regarding the strategic rationale for the delisting.